| Ytd | 130.21% | |
| 1y | 233.99% |
| Open | 106.85 | Prev Close | 106.79 | Low | 106.81 | High | 106.93 | Mkt Cap | 72.68B |
| Vol | 0.00 | Avg Vol | 3.56M | EPS | -1.04 | P/E | -102.80 | Forward P/E | -381.82 |
| Beta | 0.05 | Short Ratio | 1.56 | Inst. Own | 92.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 105.93 | 200-d Avg | 78.66 | 1yr Est | 0.00 |
Insights from Jeremy Grantham (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Jeremy Grantham (
Insights into Mario Gabelli (Trades, Portfolio)'s Investment Moves in Q4 2025 Mario Gabelli (Trades,
Insights from Jeremy Grantham (Trades, Portfolio)'s Third Quarter 2025 13F Filing Jeremy Grantham (T
Sumitomo Mitsui Trust Group Inc. increased its stake in Verona Pharma PLC American Depositary Share
Verona Pharma PLC American Depositary Share (NASDAQ: VRNA - Get Free Report) is anticipated to annou
LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron
LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA)
Posters support Ohtuvayre ® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and
Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is re
Investing in index funds is a safe way to grow your portfolio over the years. But there's a huge adv
Shield your portfolio from market swings with low-beta picks like VIPS, GDS, FUTU and VRNA, each sho
In a volatile market, low-beta picks like VIPS, ALKT, FUTU and VRNA offer investors stability with s
Does Verona Pharma PLC American Depositary Share (VRNA) have what it takes to be a top stock pick fo
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmo
Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's str
Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keyt
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Monday